In addition to finding PRR11-related mechanisms, the original study reported a cluster of E2F4-regulated genes that were sensitive to subsequent CDK4/6 inhibitor (palbociclib) treatment in a separate cohort of ER+ breast cancer patients [48]. This evidence concerns the gene CDK4 and breast cancer.